Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2023 Earnings Conference Call March 27, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer James Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Rei Tan - BTIG Robert LeBoyer - Noble Capital Markets Operator Welcome, everyone, to the Matinas BioPharma 2023 Financial Results Conference Call. Currently ...

Exhibit 99.1 Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other jurisdicti ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. [Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 (Address of principal executive of ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerry Jabbour - Chief Executive Officer Terry Matkovits - Chief Development Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Operator Welcome to the Matinas BioPharma Second Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management’s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juris ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Jody Cain – LHA Investor Relations Jerry Jabbour – Chief Executive Officer Terry Matkovits – Chief Development Officer Terry Ferguson – Chief Medical Officer Keith Kucinski – Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Operator Greetings and welcome to the Matinas BioPharma First Quarter 2023 Conference Call and Webcast. [Operator Instructions] As a remin ...

May 10, 2023 BIOPHARMA www.matinasbiopharma.com NYSE American: MTNB Lipid Nanocrystals™ (LNCs) 3 Matinas Has Developed Two Distinct Platforms for Delivering Therapeutic Cargo Phosphatidylserine and its Unique Properties Link Both Platforms 4 Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform Stable, phospholipidcalcium crystalline nanocrystals Extra-hepatic targeting • Validated Blood-Brain-Barrier penetration (MAT2203) Safe & stable • No evidence of immunogenicity or cytotoxi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...